Table 3: Tyrosine hydroxylase (TH) in brain and apomorphine-induced contralateral rotation after intravenous injection of gene therapy with TH expression plasmids.

Treatment (group) Days after Rx Apomorphine revolutions before Rx Apomorphine revolutions after Rx Striatal TH (pmol/h/mgp) Saline 3    324 ± 69* 401 ± 72 162 ± 36 6 232 ± 43 342 ± 62 288 ± 42 10 228 ± 23 331 ± 55 120 ± 18 Clone 877 3 196 ± 24       56 ± 20b    4286 ± 918b 6 231 ± 47  230 ± 55    1015 ± 213a 10 219 ± 35  256 ± 27    335 ± 79a prgTH2 3 251 ± 38    123 ± 31b       1343 ± 176b,c 6 295 ± 55    119 ± 34a    1535 ± 324b 10 344 ± 27    443 ± 70c    884 ± 7b,d prgTH3 3 317 ± 23    234 ± 38d    167 ± 35d 6 197 ± 11    127 ± 11a       545 ± 117a 10 202 ± 31    111 ± 9b,d          985 ± 101b,d prgTH4 3 211 ± 28 100 ± 9b       1219 ± 137b,c 6 234 ± 37    113 ± 20b    1621 ± 196b 10       3 ± 64  249 ± 64    500 ± 86b None NA 0 0 5068 ± 168

Rx: single IV injection of TfRMAb-targeted THLs encapsulating the respective TH expression plasmid. *Mean ± S.E. (–6 rats per point). Statistically significant differences were determined by Student’s t-test. Clone 877 is the TH expression plasmid driven by the SV40 promoter. For details in the engineering of TH genomic vectors, clones prgTH2–TH4, please see Figure 5. Difference with saline: a; b. Difference with clone 877: c; d. NA: not applicable. From [48].